ERNA or INFU or NSPR
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ERNA’s FA Score shows that 0 FA rating(s) are green whileINFU’s FA Score has 0 green FA rating(s), and NSPR’s FA Score reflects 0 green FA rating(s).
- ERNA’s FA Score: 0 green, 5 red.
- INFU’s FA Score: 0 green, 5 red.
- NSPR’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ERNA’s TA Score shows that 4 TA indicator(s) are bullish while INFU’s TA Score has 5 bullish TA indicator(s), and NSPR’s TA Score reflects 5 bullish TA indicator(s).
- ERNA’s TA Score: 4 bullish, 4 bearish.
- INFU’s TA Score: 5 bullish, 3 bearish.
- NSPR’s TA Score: 5 bullish, 4 bearish.
Price Growth
ERNA (@Biotechnology) experienced а 0.00% price change this week, while INFU (@Medical Specialties) price change was +0.64% , and NSPR (@Medical Specialties) price fluctuated +0.39% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -3.88%. For the same industry, the average monthly price growth was +15.29%, and the average quarterly price growth was -13.75%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.12%. For the same industry, the average monthly price growth was +9.23%, and the average quarterly price growth was -3.85%.
Reported Earning Dates
ERNA is expected to report earnings on Mar 12, 2025.
INFU is expected to report earnings on Aug 07, 2025.
NSPR is expected to report earnings on Aug 12, 2025.
Industries' Descriptions
@Biotechnology (-3.88% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Medical Specialties (+0.12% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| ERNA | INFU | NSPR | |
| Capitalization | 12.9M | 187M | 55.6M |
| EBITDA | -36.12M | 16.2M | -20.91M |
| Gain YTD | -29.592 | -43.787 | -3.042 |
| P/E Ratio | N/A | 195.13 | N/A |
| Revenue | 582K | 123M | 6.21M |
| Total Cash | 1.73M | 161K | 39M |
| Total Debt | 684K | 36.3M | 1.6M |
ERNA | INFU | NSPR | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 3 | 61 | 8 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 63 Fair valued | 71 Overvalued | 38 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 83 | 94 | |
PRICE GROWTH RATING 1..100 | 65 | 88 | 55 | |
P/E GROWTH RATING 1..100 | 100 | 99 | 100 | |
SEASONALITY SCORE 1..100 | n/a | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NSPR's Valuation (38) in the Medical Specialties industry is in the same range as ERNA (63) and is somewhat better than the same rating for INFU (71). This means that NSPR's stock grew similarly to ERNA’s and somewhat faster than INFU’s over the last 12 months.
NSPR's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as ERNA (100) and is in the same range as INFU (100). This means that NSPR's stock grew similarly to ERNA’s and similarly to INFU’s over the last 12 months.
INFU's SMR Rating (83) in the Medical Specialties industry is in the same range as NSPR (94) and is in the same range as ERNA (100). This means that INFU's stock grew similarly to NSPR’s and similarly to ERNA’s over the last 12 months.
NSPR's Price Growth Rating (55) in the Medical Specialties industry is in the same range as ERNA (65) and is somewhat better than the same rating for INFU (88). This means that NSPR's stock grew similarly to ERNA’s and somewhat faster than INFU’s over the last 12 months.
INFU's P/E Growth Rating (99) in the Medical Specialties industry is in the same range as NSPR (100) and is in the same range as ERNA (100). This means that INFU's stock grew similarly to NSPR’s and similarly to ERNA’s over the last 12 months.
| ERNA | INFU | NSPR | |
|---|---|---|---|
| RSI ODDS (%) | 2 days ago 80% | 2 days ago 74% | 2 days ago 85% |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 63% | 2 days ago 89% |
| Momentum ODDS (%) | 2 days ago 86% | 2 days ago 77% | 2 days ago 88% |
| MACD ODDS (%) | 2 days ago 79% | 2 days ago 77% | 2 days ago 88% |
| TrendWeek ODDS (%) | 2 days ago 84% | 2 days ago 71% | 2 days ago 79% |
| TrendMonth ODDS (%) | 2 days ago 85% | 2 days ago 80% | 2 days ago 88% |
| Advances ODDS (%) | 14 days ago 85% | 7 days ago 71% | 7 days ago 80% |
| Declines ODDS (%) | 8 days ago 90% | 3 days ago 78% | 3 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 89% | 2 days ago 77% | 2 days ago 78% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 74% | 2 days ago 78% |
ERNA and
Correlation & Price change
A.I.dvisor indicates that over the last year, ERNA has been loosely correlated with CGEN. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if ERNA jumps, then CGEN could also see price increases.
| Ticker / NAME | Correlation To ERNA | 1D Price Change % | ||
|---|---|---|---|---|
| ERNA | 100% | -0.48% | ||
| CGEN - ERNA | 39% Loosely correlated | -0.79% | ||
| MDGL - ERNA | 36% Loosely correlated | +1.25% | ||
| IBIO - ERNA | 32% Poorly correlated | -0.09% | ||
| SMMT - ERNA | 31% Poorly correlated | +0.37% | ||
| CYTK - ERNA | 29% Poorly correlated | -2.74% | ||
More | ||||
INFU and
Correlation & Price change
A.I.dvisor indicates that over the last year, INFU has been loosely correlated with ALGN. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if INFU jumps, then ALGN could also see price increases.
| Ticker / NAME | Correlation To INFU | 1D Price Change % | ||
|---|---|---|---|---|
| INFU | 100% | +1.06% | ||
| ALGN - INFU | 38% Loosely correlated | -0.49% | ||
| NVST - INFU | 37% Loosely correlated | +2.75% | ||
| SIBN - INFU | 36% Loosely correlated | +6.20% | ||
| XRAY - INFU | 35% Loosely correlated | +2.32% | ||
| SMLR - INFU | 35% Loosely correlated | -0.12% | ||
More | ||||
NSPR and
Correlation & Price change
A.I.dvisor tells us that NSPR and CORBF have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NSPR and CORBF's prices will move in lockstep.
| Ticker / NAME | Correlation To NSPR | 1D Price Change % | ||
|---|---|---|---|---|
| NSPR | 100% | +1.19% | ||
| CORBF - NSPR | 26% Poorly correlated | N/A | ||
| EW - NSPR | 24% Poorly correlated | +0.16% | ||
| MLSS - NSPR | 23% Poorly correlated | -5.14% | ||
| RSLS - NSPR | 23% Poorly correlated | -20.54% | ||
| ATRC - NSPR | 23% Poorly correlated | +1.54% | ||
More | ||||